A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

a progressive brain disorder that impacts memory, thinking and behaviour. As The Express reports, the new drug has been shown ...

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...

The U.S. Food and Drug Administration approved PTC Therapeutics, Inc.'s Kebilidi (eladocagene exuparvovec-tneq) gene therapy for the ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

The FDA has fast-tracked a drug to treat severe traumatic brain injury from Swedish pharma ... in order to get the product approved and to patients faster. NeuroSTAT works by protecting and ...

This is the first gene therapy for AADC deficiency to receive US regulatory approval and the first that can be administered directly to the brain.

Researchers have discovered that the NMDA receptor (NMDAR), known for its role in learning and memory, also stabilizes brain activity by setting baseline neural network activity.

There are now artificial intelligence programs that scan MRIs for signs of cancer, Apple AirPods that work as hearing aids and devices that decode the electrical blips of the brain to restore ...

Y-mAbs already sells one treatment for neuroblastoma, called Danyelza (naxitamab), a GD2-targeting antibody which was approved in ... a royalty stream for brain cancer drug Qarziba.